DIRS.INFO The most relevant business & tech news

☆ Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
▼ + stars: | 2024-09-26 | by ( ) www.businessinsider.com time to read: +7 min

A woman who had life-changing results on a popular weight loss drug struggled to afford it for years. AdvertisementTara Rothenhoefer, a 49-year-old Florida resident, says her life changed when she joined a clinical trial for a promising new weight-loss medication. While regulated, these compounded drugs aren't FDA-approved, raising concerns from doctors about variations in quality. The grey market of weight-loss drugs is vast and complicated. In August, Eli Lilly halved the price of its weight-loss drug Zepbound through single-dose vials — a bid to lure customers back to brand-name drugs, analysts said.

Persons: —, Tara Rothenhoefer, Rothenhoefer, Eli Lilly, She's Organizations: Service, Novo Nordisk's, Research, FDA, Pharmaceutical Locations: Florida

☆ Turning point in drug prices is around the corner, says Cantor Fitzgerald's Louise Chen
▼ + stars: | 2024-09-25 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTurning point in drug prices is around the corner, says Cantor Fitzgerald's Louise ChenLouise Chen, Cantor Fitzgerald senior analyst, joins ‘Squawk Box’ to discuss Novo Nordisk's CEO on Capitol Hill, when drug prices could start to come down, and more.

Persons: Cantor Fitzgerald's Louise Chen Louise Chen, Cantor Fitzgerald Organizations: Novo, Capitol

☆ Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
▼ + stars: | 2024-09-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Novo Nordisk 's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative treatment for opioid use disorder, according to a new study released Wednesday. The active ingredient in Ozempic, semaglutide, was associated with a "significantly lower" opioid overdose risk than other diabetes medications in people diagnosed with both Type 2 diabetes and opioid use disorder, said the paper published in JAMA Network Open. Around 3,000 people were prescribed semaglutide injections, while the remaining patients received treatments that ranged from insulins to older GLP-1s for diabetes. That reflects a 58% lower risk of opioid overdose in patients who took semaglutide, Xu said.

Persons: Dr, Rong Xu, Eli Lilly, Lilly's, Xu Organizations: Novo Nordisk, JAMA, Case Western Reserve University, Centers for Disease Control, National Center for Drug, U.S, National Institutes of Health, Novo Nordisk's Victoza Locations: London, Britain, Novo

☆ Israel steps up deadly Lebanon attacks and ExxonMobil sued over plastics recycling: Morning Rundown
▼ + stars: | 2024-09-24 | by ( Elizabeth Robinson | Elizabeth Robinson Is A Newsletter Editor For Nbc News | Based In Los Angeles. | ) www.nbcnews.com time to read: +8 min

Israel’s military warned residents in southern and eastern Lebanon to evacuate certain areas, spurring tens of thousands of people to flee their homes. The lawsuit alleges ExxonMobil misled consumers for decades, encouraging Americans to pursue a “throw-away lifestyle” and downplaying concerns about plastics’ ecological risks. Effort to change Nebraska’s electoral vote system blockedA Republican state senator’s opposition to a law changing how Nebraska allocates its electoral votes drew anger from former President Donald Trump. State Sen. Mike McDonnell wrote in a letter that he is opposed to changing Nebraska’s system — which awards electoral votes by congressional district — to a winner-take-all approach so close to Election Day. Under a winner-take-all model, Trump would be all but certain to win all of Nebraska’s electoral votes.

Persons: Fadel Itani, Israel, ”, Rob Bonta, “, Read, Donald Trump, Donald Trump . State Sen, Mike McDonnell, McDonnell, Trump, Lars Fruergaard Jørgensen, Ryan Wesley Routh, Marcellus Williams, Felicia “ Lisha ” Gayle, Bill Anders, — Elizabeth Robinson, Elizabeth Robinson Organizations: ExxonMobil, Getty, International Organization for Migration, U.S . State Department, NBC News, Republican, Donald Trump . State, drugmaker Novo Nordisk, Service, Justice Department, Trump, National Hurricane Center, King, Gettysburg College, NASA, NBC, Walmart Locations: Lebanon . California, Lebanon, Israel, Beirut, AFP, California, Nebraska, Omaha, Florida, Trump’s, Lago, Butler , Pennsylvania, Missouri, Caribbean, Colorado, Boulder, Boulder ., Pennsylvania, Spain

The head of the committee, Sen. Bernie Sanders, I-Vt., has been vocal about his frustrations over how much Novo Nordisk charges Americans for both Ozempic (used to treat type 2 diabetes) and Wegovy (approved for weight loss). Mariam Zuhaib / AP“It is clear that Novo Nordisk is ripping off the American people,” Sanders told NBC News in June. In a statement Monday, Novo Nordisk defended its pricing structure. Novo Nordisk holds the patent on semaglutide, so other companies aren't able to make a generic version. That leaves Novo Nordisk — and ultimately Jørgensen — to answer questions about the price of its blockbuster drugs.

Persons: Lars Fruergaard Jørgensen, Jørgensen, Sen, Bernie Sanders, Sanders, Mariam Zuhaib, ” Sanders, “, United States don’t, ” Organizations: Nordisk, Capitol, Health, Education, Labor, Pensions, NBC News, Novo Nordisk, Department of Health, Human Services, NBC, Novo Nordisk — Locations: Canada, Europe, United States, Germany, United Kingdom, U.S, Novo

Wegovy, the blockbuster weight loss treatment from Novo Nordisk , tops the list of drugs that could soon become part of the second round of price negotiations between manufacturers and Medicare. The Biden administration last month announced new negotiated prices for the first 10 Medicare Part D drugs selected for the talks. He also pushed back on Medicare price negotiations when asked about the potential selection of Wegovy and Ozempic, calling the talks "price-setting" that will have negative consequences for drug innovation. Medicare Part D doesn't cover weight loss treatments unless they are approved and prescribed for another health condition. We'll be following the next round of Medicare drug price negotiations closely, so stay tuned for our coverage.

Persons: Wegovy, Hollie Adams, Biden, it's, Novo, Lars Fruergaard Jørgensen, Lars Jorgensen, Ozempic, Piroschka Van De Wouw, Jørgensen, Semaglutide, We'll, Annika, annikakim.constantino Organizations: Novo Nordisk, Reuters, Specialty Pharmacy, Centers, Medicare, Medicaid Services, Health, Education, Labor, Capitol, CMS, Wall Street, GSK, Astellas Pharma, Epic Systems Locations: London, Britain, Novo, Washington , U.S

☆ ‘Greed, greed, greed’: Sanders demands Ozempic maker lower prices
▼ + stars: | 2024-09-24 | by ( Meg Tirrell | Tami Luhby | ) edition.cnn.com time to read: +7 min

“We are very committed to making sure that Americans have access at an affordable price point for our medicines,” Jorgensen replied. Similarly, Wegovy’s list price is $1,349 in the US, but it costs $186 in Denmark, $140 in Germany and $92 in the United Kingdom, he said. Tuesday’s hearing boiled down to a familiar argument over who is responsible for the US’s higher prices: drug companies that set starting – or “list” – prices or pharmacy benefit managers, the middlemen that negotiate discounts on those list prices in exchange for favorable insurance coverage and access. Jorgensen said Novo Nordisk pays back about 75% of its medicine sales in rebates, discounts and fees, so the net price it receives is far lower than the list price. “The broad totality is that less patients have access to our medicines when we lowered the price,” Jorgensen told Sen. Maggie Hassan, D-New Hampshire, after she pressed him to reduce list prices.

Persons: Sen, Bernie Sanders, ” Sanders, Lars Fruergaard Jorgensen, ” Jorgensen, “, Sanders, Jorgensen, it’s, Maggie Hassan, drugmakers, ”, PBMs, scot, ” Sen, Tim Kaine, Roger Marshall, Eli Lilly, Dr, Sanjay Gupta, Tammy Baldwin Organizations: CNN, Nordisk’s, US, Health, Education, Labor, Pensions, Yale, Novo Nordisk’s Ozempic, Novo Nordisk, Pharmaceutical Care Management Association, Nordisk, Novo Nordisk’s, Federal Trade Commission, CVS, Cigna’s, Republican, Wegovy’s, CNN Health, Medicare, Services Locations: United States, Danish, America, Canada, Denmark, Germany, United Kingdom, New Hampshire, Big, Virginia, Kansas, Novo, Wisconsin

☆ Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices
▼ + stars: | 2024-09-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks during an interview in New York on Aug. 10, 2022. Novo Nordisk 's top executive is slated to face a Senate grilling on Tuesday over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the U.S.Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate Health, Education, Labor and Pensions Committee hearing at 10 a.m. It comes roughly five months after Sen. Bernie Sanders, the Vermont independent who chairs the Senate panel, opened an investigation into the Danish drugmaker's pricing practices. Sanders contends that Novo Nordisk charges Americans substantially higher prices for its blockbuster drugs than it does for patients in other countries. Before insurance, Ozempic costs nearly $969 per month and Wegovy costs almost $1,350 per month in the U.S.

Persons: Lars Fruergaard Jørgensen, Sen, Bernie Sanders, Sanders Organizations: Novo Nordisk, Health, Education, Labor, Washington , D.C, Nordisk Locations: New York, U.S, Washington ,, Vermont, Danish, Germany

☆ Mizuho's Jared Holz talks what senate hearings mean for GLP-1 makers
▼ + stars: | 2024-09-24 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMizuho's Jared Holz talks what senate hearings mean for GLP-1 makersJared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

Persons: Jared Holz Organizations: Novo Nordisk, GLP Locations: Mizuho

☆ GLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan Seigerman
▼ + stars: | 2024-09-24 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan SeigermanEvan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.

Persons: BMO's Evan Seigerman Evan Seigerman Organizations: BMO, Novo Nordisk's

☆ Novo Nordisk CEO testifies before Senate on weight loss drug prices
▼ + stars: | 2024-09-24 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk CEO testifies before Senate on weight loss drug pricesCNBC's Angelica Peebles reports on Novo Nordisk's testimony before the Senate Health, Education, Labor, and Pensions Committee.

Persons: Angelica Peebles, Novo Organizations: Novo Nordisk, Health, Education, Labor, Pensions

☆ Depth of weight loss drug pipeline will support growth even as cost lowers, says StemPoint's Ross
▼ + stars: | 2024-09-24 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDepth of weight loss drug pipeline will support growth even as cost lowers, says StemPoint's RossMichelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC's 'Closing Bell' to discuss the criticism Novo has faced around high drug prices, the potential earnings impact if prices come down, and more.

Persons: StemPoint's Ross Michelle Ross, Novo Organizations: StemPoint Capital, Novo Nordisk

☆ Is Ozempic to blame for the slowdown in salty snack sales? Here’s the verdict
▼ + stars: | 2024-09-24 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

Sluggish salty snack sales have prompted questions about whether Ozempic and obesity treatments like Wegovy and Zepbound ae to blame. GLP-1 drugs have been cheered as an effective method to help patients with diabetes and obesity to manage their blood sugar levels, hunger and weight. Lieberman found that the temporary price reduction at Wal-Mart stores drove an increase in both the product's volume and sales, leading to the conclusion that snack sales were hurt by price pressures for consumers. "All said, the data suggests to us that the primary challenge facing the salty snack category is affordability and arguably not GLP-1s and evolving health & wellness trends as some people might opine," she wrote in the report. "The salty snack category raises prices faster than the rest of the grocery store, so we probably have more work to do to right-size the prices," he told CNBC in an interview.

Persons: Morgan Stanley, Campbell, Lauren Lieberman, Pepsi's, Lieberman, Cowen, Robert Moskow, Moskow, It's, TD Cowen, Nordisk's Wegovy, Eli Lilly's Zepbound, Dara Mohsenian, Mohsenian, There's Organizations: Pepsi, UTZ Brands, Barclays, Mart, CNBC, Nielsen Locations: confections, Nordisk's

☆ Modelo maker Constellation Brands jumps, and the S&P 500 eyes another record close
▼ + stars: | 2024-09-23 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. After struggling near the open, consumer staples is making a push higher on the daily S & P 500 sector leaderboard. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, There's, We're, Piper Sandler, Brown, Forman, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, ., Constellation Brands, Corona, Modelo, Sunday, Abbott Laboratories, GE Healthcare, Novo Nordisk, Apple, Microsoft, Nvidia, Broadcom, Motors, Starbucks, Thor, Philadelphia Federal, Conference, Richmond, Jim Cramer's Charitable

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices. PBMs work with insurance companies to negotiate discounted prices from drug companies in exchange for including the drugs in their coverage. The drug was priced at $274 in 2017, as a result of the PBMs rebate system strategy, the FTC said. In July, Democratic and Republican lawmakers blamed executives from Caremark, Express Scripts and Optum Rx for sky-high prescription drug prices in the U.S. during an oversight committee hearing. The lawsuit also comes as states — most recently Vermont — have sued PBMs, alleging they drive up drug costs.

Persons: Cigna, Eli Lilly, Rahul Rao, It’s, Raja Krishnamoorthi, PBMs Organizations: Federal Trade Commission, FTC, CVS, Cigna's, Zinc Health, Ascent Health, Emisar Pharma Services, UnitedHealth, CVS Health, Novo Nordisk, Democratic, Republican, Caremark, New York Times, Republicans, ” Rep Locations: U.S, FTC’s, Vermont

☆ FTC sues drug middlemen for allegedly inflating insulin prices
▼ + stars: | 2024-09-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen use practices that boost their profits while "artificially" inflating costs for patients. It comes three days after Express Scripts sued the FTC, demanding that the agency retract its allegedly "defamatory" July report that claimed that the PBM industry is hiking drug prices. It also alleges that PBMs favor those high-list-price insulins even when more affordable insulins with lower list prices become available. President Joe Biden's signature Inflation Reduction Act has capped insulin prices for Medicare beneficiaries at $35 per month. The FTC said it remains "deeply troubled" by the role insulin manufacturers play in higher list prices, arguing that they inflate prices in response to PBMs' demands for higher rebates.

Persons: Lina Khan, UnitedHealth, drugmakers Eli Lilly, Caremark, PBMs, Rahul Rao, Rao, Joe Biden's, Biden, Eli Lilly, Eli Lilly's Organizations: Federal Trade Commission, CVS, Cigna's, FTC, Sanofi, Novo Nordisk, Express, Competition Locations: Rayburn, Washington ,, U.S, drugmakers, FTC's

☆ Stocks making the biggest moves midday: FedEx, Nike, Constellation Energy and more
▼ + stars: | 2024-09-20 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Constellation Energy – Shares surged more than 17% after the company announced plans to restart the Three Mile Island nuclear plant and sell that power to Microsoft to satisfy the energy needs of its data centers. ASML – The semiconductor stock slid 3.4% in the wake of a Morgan Stanley downgrade to equal weight from overweight. Morgan Stanley said the risk-to-reward ratio has been "balancing." Centessa Pharmaceuticals – The biotech stock rose more than 4% after Morgan Stanley upgraded it to overweight from equal weight. Valero Energy – The energy stock declined nearly 3% after a Piper Sandler downgrade to neutral from an overweight rating, citing "less room for outperformance."

Persons: Raj Subramaniam, Elliott Hill, John Danahoe, Eli Lilly's orforglipron, Eli Lilly, Vistra, it's, Donald Trump, Lennar, ASML, Morgan Stanley, Piper Sandler, Buddy Chester, Alex Harring, Brian Evans, Samantha Subin, Yun Li, Lisa Kailai Han, Jesse Pound, Michelle Fox Organizations: FedEx, Nike, Constellation Energy, Microsoft, Novo Nordisk –, Deutsche Bank, Corbus Pharmaceuticals, Novo Nordisk's, Viking Therapeutics, Vision, Trump Media & Technology, Pharmaceuticals, Valero Energy Locations: Novo, Texas

☆ Why Eli Lilly and Palo Alto Networks are both up on news from their competitors
▼ + stars: | 2024-09-20 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Recall, that we initially had a view that competitors like Club name Palo Alto Networks would take advantage of this event to pitch their products. Sure the quarter was good because Palo Alto has a great product and value proposition, but it didn't suggest a massive departure from CrowdStrike. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Dow, It's, Eli Lilly, LLY's, Eli Lilly's, isn't, Jim Cramer's, Jim Organizations: CNBC, ., Novo Nordisk, Deutsche Bank, Palo Alto Networks, Palo Alto, Palo, KB, Micron, Jefferies, Costco, Jim Cramer's Charitable Locations: Palo

WASHINGTON — Sen. Bernie Sanders, I-Vt., renewed his criticism of drugmaker Novo Nordisk on Tuesday, claiming that the CEOs of major generic pharmaceutical companies have told him that they can produce and sell its blockbuster diabetes drug Ozempic for less than $100 a month. During Tuesday's roundtable, Sanders said his recent conversations with generic drugmakers revealed that Novo Nordisk's pricing is "nothing less than excess corporate greed." “They have studied the math, and they tell me that they can sell a generic version of Ozempic, the exact same drug that Novo Nordisk is manufacturing, to Americans for less than $100 a month," Sanders said. Sanders’ office declined to say which generic drug companies told him that they could sell Ozempic at a fraction of what Novo Nordisk charges. Novo Nordisk did not immediately respond to a request for comment.

Persons: WASHINGTON — Sen, Bernie Sanders, Sanders, Lars Fruergaard Jorgensen's, Jorgensen, Wegovy, Dale Folwell, Eli Lilly's Organizations: drugmaker Novo Nordisk, Capitol, Novo Nordisk, Health, Education, Labor, Pensions, Wegovy, Nordisk, Yale Locations: U.S, Novo, Denmark, Germany, United Kingdom, North Carolina

☆ GLP-1 pills are coming, and they could revolutionize weight-loss treatment
▼ + stars: | 2024-09-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

CNN —Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. At least a dozen similar experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing. Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience. The oral GLP-1 raceRight on the heels of oral semaglutide is a group of drugs led by Eli Lilly’s orforglipron, an oral medication that also targets GLP-1, which is a hormone implicated in insulin regulation, appetite and digestion. Drugmakers including Pfizer and Roche, as well as smaller companies like Structure Therapeutics, Terns Pharmaceuticals and Viking Therapeutics, also have oral weight-loss drugs in earlier stages of development, BMO research shows.

Persons: Jared Holz, ” Holz, ”, Jody Dushay, Dushay, ” Dushay, it’s, Rybelsus, Jorge Moreno, “, ” Moreno, Eli Lilly’s orforglipron, Lilly, Evan Seigerman, amycretin, who’ve, Dr, Sanjay Gupta, Holz, he’s, he’d Organizations: CNN, Harvard Medical School, Beth Israel Deaconess Medical, Novo Nordisk, US Food and Drug Administration, Yale School of Medicine, BMO Capital Markets, Pfizer, Roche, Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, BMO, Nordisk, European Association for, Diabetes, Inversago Pharma, CNN Health Locations: Danish, Novo

☆ Novo Nordisk shares sink on medicare price negotiation fears
▼ + stars: | 2024-09-17 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk shares sink on medicare price negotiation fearsJared Holz, Mizuho, joins 'Fast Money' to talk how possible Medicare price negotiations are impacting Novo Nordisk shares.

Persons: Jared Holz Organizations: Novo Nordisk Locations: Mizuho

☆ How the Research Triangle has helped make North Carolina one of America's fastest-growing economies
▼ + stars: | 2024-09-16 | by ( Natalie Rice | ) www.cnbc.com time to read: +2 min

North Carolina's Research Triangle is one of the fastest-growing areas in the U.S., with a population that's boomed by 5.6% since 2020 to 2.4 million people, according to Census data. The area, also known simply as "The Triangle," is anchored by Raleigh, Durham and Chapel Hill and their major universities: North Carolina State University, Duke University and the University of North Carolina at Chapel Hill. And in that 50 years, North Carolina has totally restructured its economy," said Michael Walden Reynolds, an economics professor at North Carolina State University. The Triangle region has about 4,000 tech and 600 life science companies, and more than 300 companies are headquartered in RTP alone, according to the Research Triangle Regional Partnership and Work In The Triangle. "Companies are seeing the advantages of doing business here," said Ryan Combs, executive director of the Research Triangle Regional Partnership.

Persons: I've, Michael Walden Reynolds, Apple, it's, Ryan Combs Organizations: Chapel Hill, North Carolina State University, Duke University, University of North, RTP, North, Research Triangle Regional, Meta, Novo Nordisk, Google, Apple, Nordisk, CNBC, Business . Locations: U.S, Raleigh, Durham, University of North Carolina, North Carolina, RTP, States

☆ Kate Moss' half-sister Lottie Moss, 26, says she ended up in the hospital after using Ozempic that she got from a friend
▼ + stars: | 2024-09-13 | by ( Amanda Goh | ) www.businessinsider.com time to read: +4 min

Read previewLottie Moss, 26, is speaking out about the dangers of taking Ozempic. During an episode of her "Dream On" podcast, the model — who is Kate Moss' half-sister — said she ended up in a hospital after taking the drug. Moss said she went to the hospital after a particularly bad day when she couldn't keep any liquids or food down. Reflecting on her use of Ozempic, Moss called it "the worst decision I ever made." AdvertisementLast year in Austria, several people were brought to the hospital with life-threatening seizures after taking counterfeit versions of the drug.

Persons: —, Lottie Moss, Kate Moss, I'm, Moss, didn't, Eric Kastango, Ozempic, semaglutide Organizations: Service, Business, Novo Nordisk, FDA, Austrian Federal Office, Safety, Health Care Locations: Austria

☆ Digital health company Noom to offer compounded GLP-1 drug through new weight loss program
▼ + stars: | 2024-09-12 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +5 min

Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149. Noom has offered weight loss programs for years, and consumers can already try to access those branded medications through its platform. Compounded GLP-1 medications are typically much cheaper than their branded counterparts. Most insurance plans cover GLP-1s when they are used to treat diabetes, but coverage of the weight loss drugs is less widespread. Consumers can get started with the Noom GLP-1 RX program by filling out an intake form on the website.

Persons: Wegovy, Noom, Geoff Cook, Cook, Dr, Adonis Saremi, They'll Organizations: CNBC, U.S . Food, Drug Administration, FDA Locations: U.S, United States

☆ Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer's drugs
▼ + stars: | 2024-09-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland. Eli Lilly also announced an $800 million facility expansion in Kinsale, Ireland. Eli Lilly has invested more than $20 billion to buy, build and expand manufacturing plants in the U.S. and Europe since 2020. Eli Lilly's main rival in the weight loss drug space, Novo Nordisk , has similarly poured in billions to boost production of its own treatments.

Persons: Eli Lilly, Eli, Edgardo Hernandez, Eli Lilly's Organizations: Novo Nordisk Locations: Indianapolis , Indiana, Ireland, Limerick, U.S, Kinsale, Europe, Novo

Search resuls for: "nordisk"

25 mentions found